Nonmelanoma Skin Cancer Pipeline Analysis Report 2026

Nonmelanoma skin cancer, primarily comprising basal cell carcinoma and cutaneous squamous cell carcinoma, represents one of the most common malignancies worldwide and a growing public health concern. According to Mingyue Wang et al., 2024, estimates, nonmelanoma skin cancers were the fifth most common cancer globally, with approximately 1,234,533 new cases and around 69,416 deaths reported worldwide in that year. Its prevalence continues to rise, particularly among aging populations and regions with high ultraviolet exposure, contributing to a substantial healthcare burden despite relatively low mortality. The nonmelanoma skin cancer pipeline analysis highlights continued innovation across emerging therapies for nonmelanoma skin cancer aimed at improving long-term disease control.

Report Coverage

The Nonmelanoma Skin Cancer Pipeline Analysis Report gives comprehensive insights into nonmelanoma skin cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for nonmelanoma skin cancer. The nonmelanoma skin cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The nonmelanoma skin cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with nonmelanoma skin cancer treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to nonmelanoma skin cancer.

Nonmelanoma Skin Cancer Pipeline Outlook

Nonmelanoma skin cancer is a group of malignancies, primarily basal cell carcinoma and squamous cell carcinoma, arising from abnormal growth of skin cells due to prolonged ultraviolet radiation exposure. Genetic mutations, environmental factors, and immune suppression contribute to its development, driving advancements in the novel targeted therapies for skin cancer pipeline.

Nonmelanoma skin cancer treatment includes surgical excision, radiation therapy, and evolving options such as immunotherapy pipeline for nonmelanoma skin cancer and topical treatments in skin cancer pipeline, enhancing precision, efficacy, and patient outcomes. In October 2025, FDA approved cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adults with high-risk CSCC following surgery and radiotherapy, aimed at lowering the risk of disease recurrence. Emerging agents in trials seek enhanced efficacy with favorable safety profiles.

Nonmelanoma Skin Cancer Epidemiology

Nonmelanoma skin cancers, primarily basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are among the most frequently diagnosed cancers worldwide. According to Mingyue Wang et al., 2024, there were an estimated 1.23 million new NMSC cases and about 69,000 deaths globally in that year, ranking NMSC fifth in overall cancer incidence. Incidence is highest in high-income regions such as Australasia, North America, and Europe, driven by ultraviolet exposure and aging populations, while rates in Asia and Africa remain lower. The nonmelanoma skin cancer burden continues to increase with demographic shifts and enhanced detection.

Nonmelanoma Skin Cancer - Pipeline Therapeutic Assessment

This section of the report covers the analysis of nonmelanoma skin cancer drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase 1)
• Preclinical and Discovery Stage Products

By Drug Class

The nonmelanoma skin cancer pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Peptides
• Polymers
• Gene Therapies

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Nonmelanoma Skin Cancer Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total nonmelanoma skin cancer clinical trials. The phase 1 covers 28%, phase 2 accounts for 44%, phase 3 covers 22% drugs, providing an in-depth analysis of each. The early phase 1 covers nearly 6% of investigational drugs for skin cancer treatment.

Nonmelanoma Skin Cancer Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the nonmelanoma skin cancer pipeline analysis include monoclonal antibodies, small molecules, peptides, polymers, and gene therapies. The nonmelanoma skin cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for nonmelanoma skin cancer. For instance, in December 2024, the FDA approved cosibelimab-ipdl (Unloxcyt) for adults with advanced cutaneous squamous cell carcinoma that is locally advanced or metastatic and not suitable for curative surgery or radiotherapy.

Nonmelanoma Skin Cancer Clinical Trials - Key Players

The report for the nonmelanoma skin cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed nonmelanoma skin cancer therapeutic assessment, analysing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in nonmelanoma skin cancer clinical trials:

• Phio Pharmaceuticals Inc.
• Onchilles Pharma Inc.
• AstraZeneca
• KaliVir Immunotherapeutics
• Regeneron Pharmaceuticals
• Stamford Pharmaceuticals, Inc.
• Sirnaomics
• AiViva BioPharma, Inc.
• Feldan Therapeutics
• Verrica Pharmaceuticals Inc.

Nonmelanoma Skin Cancer - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for nonmelanoma skin cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of nonmelanoma skin cancer drug candidates.

Drug: Cemiplimab

Cemiplimab (LIBTAYO) is being evaluated in a Phase 3 C-POST trial sponsored by Regeneron Pharmaceuticals in collaboration with Sanofi. The study examines its efficacy in preventing recurrence of high-risk cutaneous squamous cell carcinoma following surgery and radiation. Cemiplimab is a monoclonal antibody targeting the PD-1 receptor, enhancing immune-mediated tumor cell destruction, and is administered intravenously. The trial is demonstrating improved disease-free survival compared to placebo, with ongoing follow-up expected to continue through approximately 2030.

Drug: AZD6750

AZD6750 is a novel CD8‑guided interleukin‑2 (IL‑2) agent being evaluated for safety, pharmacokinetics and efficacy in advanced or metastatic solid tumors, including cutaneous squamous cell carcinoma (a form of nonmelanoma skin cancer). It may be administered alone or with other anticancer agents to stimulate immune‑mediated tumor control. AstraZeneca, a global biopharmaceutical leader in oncology, is conducting this Phase 1/2 clinical study as part of its broad immuno‑oncology pipeline. The study is expected to be completed by February 2029.

Drug: RP1

RP1 (vusolimogene oderparepvec) is being developed by Replimune Inc. as an oncolytic immunotherapy for nonmelanoma skin cancer. The Phase 2 IGNYTE study is evaluating safety and estimating efficacy of RP1, administered via intratumoral injection, both as monotherapy and in combination with nivolumab. The drug is engineered from a modified herpes simplex virus expressing GM-CSF and a fusogenic protein to enhance tumor cell lysis and systemic immune activation. The study is expected to be be completed by December 2028.

Key Questions Answered in the Nonmelanoma Skin Cancer Pipeline Insight Report

• Which companies/institutions are leading the nonmelanoma skin cancer drug development?
• Which company is leading the nonmelanoma skin cancer pipeline development activities?
• What is the current nonmelanoma skin cancer commercial assessment?
• What are the opportunities and challenges present in the nonmelanoma skin cancer pipeline landscape?
• What is the efficacy and safety profile of nonmelanoma skin cancer pipeline drugs?
• Which company is conducting major trials for nonmelanoma skin cancer drugs?
• Which companies/institutions are involved in nonmelanoma skin cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in nonmelanoma skin cancer?

Reasons To Buy This Report

The Nonmelanoma Skin Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for nonmelanoma skin cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into nonmelanoma skin cancer collaborations, regulatory environments, and potential growth opportunities.